Can a milk sugar tame IBD symptoms?

NCT ID NCT03847467

Completed Disease control Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing whether a prebiotic supplement called 2'-FL, found in human milk, can safely ease gut symptoms in young people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Participants, aged 11 to 25, are in remission and already taking anti-TNF medications. They will receive either 2'-FL or a placebo daily, and researchers will measure changes in gut symptoms and beneficial bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 2'-Fucosyllactose (2'-FL), a prebiotic dietary supplement
What this could lead to: If effective, 2'-FL could become a simple dietary supplement to help manage IBD symptoms and improve gut health in young patients.
What could go wrong: This is an early-phase trial, so results may not be conclusive. The supplement might not improve symptoms or could cause digestive discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE INFLAMMATORY BOWEL DISEASES ULCERATIVE COLITIS

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Connecticut Children's Medical Center

Hartford, Connecticut, 06106, United States
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.